SCHEMBL2389657

SCHEMBL2389657

O=C(C=P(c1ccccc1)(c1ccccc1)c1ccccc1)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.57
LMNA P02545 3/20 0.54
ALDH1A1 P00352 5/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
AKR1B10 O60218 2/20 0.50
AKR1B1 P15121 2/20 0.50
CA12 O43570 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
HSP90AA1 P07900 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12305763 1.00 HCAR2 (0.57) HCAR2LMNAALDH1A1MAPK1L3MBTL1
SCHEMBL11709722 0.87 ATM (0.48) HCAR2ALDH1A1POLBSMN1; SMN2
SCHEMBL10636434 0.85 RAB9A (0.52) ALDH1A1TDP1KMT2A
SCHEMBL65066 0.81 HSP90AA1 (0.50) HCAR2LMNAALDH1A1HSP90AA1KMT2A
SCHEMBL7907406 0.81 HSP90AA1 (0.54) HCAR2LMNAALDH1A1MAPK1L3MBTL1
Bromide SCHEMBL6879691 0.79 HSP90AA1 (0.49) HCAR2LMNAALDH1A1HSP90AA1KMT2A
Hydrochloric Acid SCHEMBL9061399 0.79 HSP90AA1 (0.49) LMNAALDH1A1HSP90AA1KMT2APOLB
SCHEMBL2392064 0.78 LMNA (0.50) HCAR2LMNAALDH1A1L3MBTL1TDP1
SCHEMBL6290042 0.78 HSP90AA1 (0.47) HCAR2LMNAALDH1A1MAPK1L3MBTL1
SCHEMBL1501229 0.78 PKM (0.54) LMNAALDH1A1MAPK1HSP90AA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054877-A1 Enantiomerically selective cyclopropanation TAYLOR DENNIS (AU) 2005-03-10 US claimed
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-10-09 US disclosed
EP-4619386-A1 ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-09-24 EP disclosed
EP-4577526-A1 VHH ANTIBODY CONJUGATES Abdera Therapeutics Inc. (US) 2025-07-02 EP disclosed
WO-2025101944-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Plexium, Inc. (US) 2025-05-15 WO disclosed
EP-4522628-A2 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-03-19 EP disclosed
EP-3788043-B1 SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS MERCK SHARP & DOHME LLC (US) 2024-11-06 EP disclosed
US-12091425-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2024-09-17 US disclosed
WO-2024104932-A1 ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-05-23 WO disclosed
US-11964988-B2 Fused heterocyclic compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2024-04-23 US disclosed
EP-0067518-B1 MODIFIED BETA-LACTAM COMPOUNDS BEECHAM GROUP PLC (GB) 1985-08-21 EP disclosed
EP-0136721-A2 Carboxyalkenamidocephalosporins SHIONOGI & CO., LTD. (JP) 1985-04-10 EP disclosed
EP-0035689-B1 4-SUBSTITUTED-2-OXOAZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE FOR PREPARING ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-12-19 EP disclosed
US-4463010-A 1-Aza-[3.2.0]-bicycloheptane-2-carboxylic acid, ester or salt thereof BEECHAM GROUP P.L.C. (GB) 1984-07-31 US disclosed
US-4383945-A 4-Substituted-2-oxoazetidine compounds and processes for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-05-17 US disclosed
EP-0067518-A1 Modified beta-lactam compounds BEECHAM GROUP PLC (GB) 1982-12-22 EP disclosed
US-4361514-A Carbon analogs of penicillin MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1982-11-30 US disclosed
EP-0035689-A1 4-Substituted-2-oxoazetidine compounds, processes for their preparation, and their use for preparing antibiotics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-09-16 EP disclosed
US-4282149-A Carbon and oxygen analogs of penicillin MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1981-08-04 US disclosed
US-4143046-A CARBON AND OXYGEN ANALOGS OF PENICILLIN MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964988-B2 Fused heterocyclic compounds as RET kinase inhibitors RET, ROR1, FRK HCAR2 1847/4885LMNA 2219/4885ALDH1A1 3607/4885
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF POLRMT, TARDBP, NSUN2 HCAR2 1701/4885LMNA 1138/4885ALDH1A1 3858/4885
US-20050054877-A1 Enantiomerically selective cyclopropanation CDY1; CDY1B, DYRK2, DYRK4 HCAR2 2026/4885LMNA 2016/4885ALDH1A1 1988/4885
US-12091425-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 HCAR2 4790/4885LMNA 1191/4885ALDH1A1 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.